S

Sanofi

Global pharma company; vaccines and R&D

Institutional Account Director - Rare Blood Disorder, CABLIVI

Full-TimePosted on 10/21/2026Deadline 1/21/27
$146.3k - $243.8k
Senior
Bachelor's
Tennessee, USA+1 moreMore locations: Kentucky, USA
RemoteRemote role covering institutional accounts in Tennessee and Kentucky.
Sales & Account ManagementAccount Management

About the job

Requirements
  • A bachelor's degree is required; an advanced degree is preferred.
  • A valid driver's license is required.
  • At least five years of relevant work experience is required.
  • At least two years of institutional account management experience is required.
  • A consultative mindset for creative problem solving with customers' needs as a primary focus, with experience in strategic account planning and selling.
  • Strong communication, presentation, and negotiation skills, including the ability to understand and communicate health economic information effectively.
  • Ability to shape the system by gaining deep insights into business needs and developing value propositions that deliver joint value.
  • Ability to align the system by facilitating implementation internally and externally.
  • Ability to gain insights by understanding connections and beliefs across the ecosystem.
  • Organization, dependability, self-motivation, and ability to use planning tools in a fast-paced environment.
  • IDN knowledge is preferred.
  • Current customer relationships in the assigned geography or institutional accounts are ideal.
  • Five years of healthcare sales or account management experience, including direct market access or First Line Manager experience, is preferred.
  • Hospital inpatient experience is preferred.
  • Hematology products and physician reimbursement experience are preferred.
  • Significant experience and understanding of the changing payer environment and its impact on patient access to products infused in provider offices and healthcare facility settings is preferred.
  • Must achieve and maintain compliance with applicable company policies and procedures and regulatory and legal requirements.
Responsibilities
  • Develop in-depth knowledge of each assigned customer account, including strategic goals, value drivers, key access stakeholders, relevant business metrics, challenges, and emerging needs.
  • Support clinical advocacy, including gaining key opinion leader endorsement, and develop and implement strategies and tactics to support access coverage on provider pathways, electronic medical records, and formularies.
  • Develop knowledge of the CABLIVI Artificial Intelligence Model and leverage the CABLIVI efficacy and safety message to support brand needs.
  • Integrate customer business segmentation into product objective planning and execution.
  • Understand product access processes at institutional accounts, including Requests for Proposals, Pharmacy and Therapeutics Committee workflows, key stakeholders, relevant financial models such as Budget Impact Models, and clinical evaluation models.
  • Develop and deepen strategic partnerships with C-suite and D-suite executives and population health decision makers, expanding relationships to broader customer stakeholders involved in account-level access.
  • Support pull-through of CABLIVI at targeted Integrated Delivery Networks and support establishment of acquired thrombotic thrombocytopenic purpura protocols as applicable.
  • Work with internal trade and channel partners on distribution issues and with the channel operations team to maintain product access.
  • Create clear messages for dissemination to cross-functional field teams, including field sales, payer account teams, thought leader liaisons, and patient support services.
  • Maintain open and transparent communication throughout the company regarding business-unit and cross-business-unit initiatives with similar accounts.
  • Ensure compliance with applicable company policies and procedures and regulatory and legal requirements, including requiring the same of the team.
Desired Qualifications
  • Advanced degree.
  • IDN knowledge.
  • Current customer relationships in the assigned geography or institutional accounts.
  • At least five years of healthcare sales or account management experience, including direct market access or First Line Manager experience.
  • Hospital inpatient experience.
  • Hematology products and physician reimbursement experience.
  • Significant experience and understanding of the changing payer environment and its impact on patient access to products infused in provider offices and healthcare facility settings.

About the company

Sanofi is a global pharmaceutical and biotechnology company that develops, manufactures, and sells prescription medicines, over-the-counter products, and vaccines. Its products span immunology, oncology, rare diseases, and vaccines, addressing unmet medical needs through a strong focus on research and development. Sanofi's core product model relies on large-scale R&D, strategic partnerships, and licensing to bring new therapies to markets, with revenue generated from product sales and collaborations. The company differentiates itself by leveraging its global reach, diverse portfolio, and emphasis on patient-centric solutions, safety, and quality to navigate regulatory environments in developed and emerging markets. The company’s goal is to improve health outcomes and quality of life for people worldwide by delivering innovative treatments and vaccines that meet unmet medical needs.

Company Size

10,001+

Company Stage

IPO

Headquarters

Paris, France

Founded

1973

Get referred to Sanofi

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • July 10, 2026 FDA approval of Sarclisa Escena created the first on-body cancer injector.
  • June 13, 2026 FDA accelerated approval expanded Tzield into recently diagnosed stage 3 T1D.
  • Q2 2026 sales grew 17.8% at CER, with Dupixent and Beyfortus leading.

What critics are saying

  • Texas sued Sanofi on February 19, 2026 over provider bribery and Medicaid fraud.
  • Sanofi sued Pfizer and Moderna on July 15, 2026, extending costly mRNA patent warfare.
  • Dupixent concentration makes 2030s patent loss an existential revenue shock.

What makes Sanofi unique

  • Dupixent reached €5.2 billion quarterly sales in Q2 2026 across nine indications.
  • October 1, 2026, Sanofi and Regeneron added four long-acting antibodies to their Alliance.
  • Sanofi's 61-project pipeline spans immunology, rare diseases, vaccines, neurology, and oncology.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • Professional Development Budget
  • Parental Leave

Company News

Associated Press
Oct 19th, 2026
Enable Injections wins first Japan approval for enFuse on-body injector via Sanofi's CirCLIQ

Enable Injections has won its first commercial product approval in Japan. The country's Ministry of Health, Labour and Welfare approved the company's enFuse On-Body Delivery System through Sanofi's CirCLIQ Injector. The device delivers a subcutaneous form of Sarclisa (isatuximab) with the push of a button, for treating multiple myeloma. It is the first anticancer treatment given through an on-body injector in Japan. The approval follows recent clearances in the US and Europe. Japan approved Sarclisa SC in June 2026, backed by the IRAKLIA phase 3 study, which showed the subcutaneous form was non-inferior to intravenous delivery. "We're proud to partner with Sanofi to bring our enFuse technology to patients in Japan," said Michael D. Hooven, chairman and chief executive officer of Enable.

Yahoo Finance
Oct 1st, 2026
Sanofi, Regeneron expand alliance in up to $8B deal for immunology drugs

France's Sanofi and US-based Regeneron Pharmaceuticals will expand their 20-year partnership to jointly develop and market immunology medicines in a deal worth up to $8 billion. Regeneron will receive $1 billion upfront, with potential additional payments of up to $7 billion tied to development, regulatory, and commercial targets. The collaboration will add four next-generation immunology drug candidates invented by Regeneron, with one currently in early-stage trials for eczema. The companies will equally share development costs and future profits from new drugs, whilst their existing profit-sharing agreement for top-selling medicine Dupixent remains unchanged. The deal settles prior litigation between the companies and marks an early move by Sanofi's new chief executive Belen Garijo to strengthen the company's pipeline.

Sanofi
Sep 20th, 2026
Press Release: Sanofi completes acquisition of Vicebio

Sanofi completes acquisition of Vicebio Paris, December 4, 2025. Sanofi announces the completion of its acquisition of Vicebio Ltd (“Vicebio”). This acquisition brings an early-stage combination...

Sanofi
Sep 20th, 2026
Press Release: Sanofi completes acquisition of Blueprint Medicines

Sanofi completes acquisition of Blueprint Medicines Paris, July 18, 2025. Sanofi today announces the completion of its acquisition of Blueprint Medicines Corporation (Blueprint), adding to its...

Sanofi
Sep 20th, 2026
Press Release: Sanofi completes the acquisition of Dynavax

Sanofi completes the acquisition of Dynavax Paris, February 10, 2026. Sanofi today announced that it has completed the acquisition of Dynavax Technologies Corporation (Dynavax). The acquisition...